When should we measure lipoprotein (a)?
Key result
Lipoprotein (a) measurement for cardiovascular risk assessment is currently limited by the lack of definite intervention studies showing that lowering Lp(a) reduces hard cardiovascular endpoints.
Population
Moderate and high-risk individuals for cardiovascular disease
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Lp(a) adds little to current risk assessment or management; leaves open whether targeted lowering improves hard endpoints in trials.
Key Points
- The research aims to clarify when lipoprotein (a) should be measured and how to manage elevated levels in cardiovascular disease risk contexts.
- Analysis of epidemiological and genetic studies on lipoprotein (a) and cardiovascular disease.
- Review of therapeutic agents with Lp(a)-lowering effects currently in clinical trials.
- Assessment of current recommendations by scientific societies regarding routine Lp(a) measurement.
- A strong causal relationship exists between elevated Lp(a) levels and cardiovascular disease, independent of other risk factors.
- New therapeutic options are being developed but lack conclusive intervention studies to prove they reduce severe cardiovascular outcomes.
- Current recommendations state that Lp(a) measurement should be routine for assessing risk, especially among moderate and high-risk individuals.
Structured PICO
P
Population
Moderate and high-risk individuals for cardiovascular disease
I
Intervention
Measurement of lipoprotein (a) [Lp(a)] and Lp(a)-lowering therapies
This review highlights the causal role of Lp(a) in cardiovascular disease and provides expert guidance on its measurement and management in moderate and high-risk individuals despite current gaps in targeted therapies and outcome data.
Limitations
- Lack of definite intervention studies demonstrating that lowering Lp(a) reduces hard CVD endpoints
- Lack of effective medications for lowering Lp(a)
- Highly variable Lp(a) concentrations among different ethnic groups
- Challenges associated with Lp(a) measurement
- lack of definite intervention studies demonstrating that lowering Lp(a) reduces hard CVD endpoints
- lack of effective medications for lowering Lp(a)
- highly variable Lp(a) concentrations among different ethnic groups
- challenges associated with Lp(a) measurement
Cite This Study
Kostner et al. (2013) conducted a review in Cardiovascular disease. Lipoprotein (a) measurement was evaluated. Lipoprotein (a) measurement for cardiovascular risk assessment is currently limited by the lack of definite intervention studies showing that lowering Lp(a) reduces hard cardiovascular endpoints.